Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events included hypertension and anemia. Evidence ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Intas Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...

Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment ...

The panelist discusses, for intermediate-stage unresectable hepatocellular carcinoma (uHCC), key clinical pearls include prioritizing transarterial chemoembolization (TACE) as a first-line therapy, ...

VANCOUVER, Washington, March 18, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, ...

A phase II trial shows that pembrolizumab and bevacizumab yield a 54.1% intracranial response rate and a median overall ...

A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease ...

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Preclinical models of Parkinson's disease (PD) have been developed using intracerebroventricular (i.c.v.) injection of 6-hydroxydopamine (6-OHDA) to induce neurodegeneration and motor dysfunction.

Bradley Monk shares key insights and breakthroughs in gynaecologic oncology from ESGO 2025, shaping cancer care's future.

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.